LAWRENCE DONEHOWER to Disease Models, Animal
This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Disease Models, Animal.
Connection Strength
0.910
-
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer. 2009 11; 9(11):831-41.
Score: 0.159
-
The utility of genetically altered mouse models for cancer research. Mutat Res. 2005 Aug 25; 576(1-2):1-3.
Score: 0.120
-
Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res. 2005 Aug 25; 576(1-2):4-21.
Score: 0.120
-
The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol. 2001; 29 Suppl:24-9.
Score: 0.087
-
Mouse models in tumor suppression. Oncogene. 1998 Dec 24; 17(25):3385-400.
Score: 0.076
-
Murine tumor suppressor models. Mutat Res. 1998 May 25; 400(1-2):391-407.
Score: 0.073
-
Enhanced inflammation and attenuated tumor suppressor pathways are associated with oncogene-induced lung tumors in aged mice. Aging Cell. 2018 02; 17(1).
Score: 0.070
-
Insights into aging obtained from p53 mutant mouse models. Ann N Y Acad Sci. 2004 Jun; 1019:171-7.
Score: 0.028
-
K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications. Dis Model Mech. 2022 02 01; 15(2).
Score: 0.023
-
p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci. 1999 Jan; 55(1):38-47.
Score: 0.019
-
Genetic instability in animal tumorigenesis models. Cancer Surv. 1997; 29:329-52.
Score: 0.016
-
Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential. BMC Cancer. 2016 11 08; 16(1):869.
Score: 0.016
-
The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol. 1996 Oct; 7(5):269-78.
Score: 0.016
-
Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995 Sep; 14(1):16-22.
Score: 0.015
-
Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol. 1995 Aug; 15(8):4249-59.
Score: 0.015
-
Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
Score: 0.015
-
Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol. 2011 Aug; 224(4):540-52.
Score: 0.011
-
Early development of histiocytic sarcomas in p53 knockout mice treated with N-bis(2-hydroxypropyl)nitrosamine. Oncol Rep. 2007 Oct; 18(4):755-61.
Score: 0.009
-
Transgenic tumor models for carcinogen identification: the heterozygous Trp53-deficient and RasH2 mouse lines. Mutat Res. 2003 Oct 07; 540(2):165-76.
Score: 0.007
-
High susceptibility of nullizygous p53 knockout mice to colorectal tumor induction by 1,2-dimethylhydrazine. J Cancer Res Clin Oncol. 2003 Jun; 129(6):335-40.
Score: 0.006
-
Elevated susceptibility of the p53 knockout mouse esophagus to methyl-N-amylnitrosamine carcinogenesis. Carcinogenesis. 2002 Sep; 23(9):1541-7.
Score: 0.006
-
Transgenic mouse models for tumour-suppressor genes. J Intern Med. 1995 Sep; 238(3):233-8.
Score: 0.004